Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding Study

European Urology

Volumn 56, Issue 1, 2009, Pages 184-192

  Martínez García, Roberto ^a   Abadías, Montserrat ^b   Arañó, Pere ^c   Perales, Lorenzo ^d   Ruíz, José Luis ^e   Sust, Mariano ^b   Conejero, Juan ^f  

^a UNIVERSITY OF VALENCIA   (Spain)

^b ESTEVE   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cizolirtine citrate; Efficacy; Overactive bladder; Safety; Tolerability; Urinary incontinence

Indexed keywords

CIZOLIRTINE; PLACEBO;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; NAUSEA; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY FREQUENCY; URINE INCONTINENCE; URODYNAMICS; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CALCITONIN GENE-RELATED PEPTIDE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; PILOT PROJECTS; PYRAZOLES; SUBSTANCE P; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS; VISION DISORDERS; VOMITING; YOUNG ADULT;

EID: 67349161877     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.027     Document Type: Article

References (28)

1. Norton P., and Brubaker L. Urinary incontinence in women. Lancet 367 (2006) 57-67
2. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of Lower Urinary Tract Function: report from the Standardisation Sub-committee of the International Continence Society. Neurouro Urrodyn 21 (2002) 167-178
3. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306-1315
4. Reeves P., Irwin D., Kelleher C., et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50 (2006) 1050-1057
5. Andersson K.-E., and Wein A.J. Pharmacology of the lower urinary tract: basis for current and future treatment of urinary incontinence. Pharmacol Rev 56 (2004) 581-631
6. Yu Y.F., Nichol M., Yu P.A., and Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value Health 8 (2005) 495-505
7. Haab F., and Castro-Díaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59 (2005) 931-937
8. Aubel B., Kayser V., Farre A., Hamon M., and Bourgoin S. Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. Neuropharmacology 52 (2007) 487-496
9. Aubel B., Kayser V., Mauborgne A., Farre A., Hamon M., and Bourgoin S. Antihyperalgesic effects of cizolirtine in diabetic rats: behavioral and biochemical studies. Pain 110 (2004) 22-32
10. Ballet S., Aubel B., Mauborgne A., et al. The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology 40 (2001) 578-589
11. Montier F., Caruette A., Moussaqui S., Boccio D., and Garret C. Antagonism of substance P and related peptides by RP 67580 and CP-96345, at tachykinin Nk1 receptor sites, in the rat urinary bladder. Eur J Pharmacol 251 (1994) 9-14
12. Sáenz de Tejada I. Evaluation of the effects of the administration of cizolirtine and other seven molecules on urodynamic function in rats. Instituto de Medicina Sexual (Madrid) 2005; Esteve unpublished data.
13. Cizolirtine Investigator's Brochure, 18th edition. April 2007.
14. Chapple C.R., Rechberger T., Al-shukri S., et al., on behalf of the YM-905 Study Group. Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International 93 (2004) 303-310
15. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial. Eur Urol 48 (2005) 464-470
16. Dmochowski R., Abrams P., Marschall-Kehrel D., Wang J.T., and Guan Z. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 51 (2007) 1054-1064
17. Lee J.G., Hong J.Y., Choo M.S., et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian Patients. Int J Urol 9 (2002) 247-252
18. Mattiasson A., Blaakaer J., Hoye K., Wein A.J., and theTolterodine Scandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 91 (2003) 54-60
19. Landis J.R., Kaplan S., Swift S., and Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 171 (2004) 752-756
20. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45 (2004) 420-429
21. Malone-Lee J., Shaffu B., Anand C., and Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 165 (2001) 1452-1456
22. Davila G.W., Daugherty C.A., Sanders S.W., and Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 166 (2001) 140-145
23. Burgio K.L., Locher J.L., and Goode P.S. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 48 (2000) 370-374
24. Chapple Ch., Van Kerebroeck Ph., Tubaro A., et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52 (2007) 1204-1212
25. Diokno A.C., Appell R.A., Sand P.K., et al., the OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78 (2003) 687-695
26. Kreder K., Mayne C., and Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 41 (2002) 588-595
27. Dmochowsi R.R., Davila G.W., Zinner N.R., et al., for the Transdermal Oxybutynin Study Group. J Urol 168 (2002) 580-586
28. Lecci A., and Maggi C.A. Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept 101 (2001) 1-18